Craig-Hallum initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart
- Eledon Pharmaceuticals: Promising Advances in Organ Transplant Rejection Prevention with Tegoprubart
- Eledon Pharmaceuticals’ Tegoprubart: Promising Clinical Potential in Kidney Transplantation and Strategic Targeting Advantages
- Sernova enters collaborative research agreement with Eledon Pharmaceuticals
- Eledon Pharmaceuticals assumed with a Buy at H.C. Wainwright